Thursday, 18 June 2020
Parasitic worms could offer a new treatment hope for patients suffering from the autoimmune disease multiple sclerosis, according to experts from the University of Nottingham.
The findings of the research, published in the journal JAMA Neurology, show that infecting MS patients with a safe dose of the hookworm parasite Necator americanus induces immunoregulatory responses and boosts the number of cells which help keep the immune system under control.
The research was led by Cris Constantinescu, Professor of Neurology in the University’s School of Clinical Sciences and a leading MS expert, and David Idris Pritchard, Professor of Parasite Immunology in the University’s School of Pharmacy, who has spent decades studying the biology of the hookworm. The study was funded by the Multiple Sclerosis Society.
MS is a condition that can affect the brain and spinal cord, causing a wide range of potential symptoms, including problems with vision, arm or leg movement, sensation or balance. Whilst treatments are available, there is currently no cure.
The study aimed to show that the presence of hookworms in the body switches off the mechanism by which the body’s immune system becomes overactive — the main cause of MS — reducing both the severity of symptoms and the number of relapses experienced by the patients.
71 patients were recruited for a controlled clinical trial who suffer from the most common type of the disease, relapsing remitting MS (RRMS).
Symptoms in patients such as vision problems, dizziness and fatigue, appear and then fade away either partially or completely, and secondary progressive MS with superimposed relapses.
Half of the patients on the trial, received a low dose of the hookworms —25 of the microscopic larvae — on a plaster applied to the arm, while the other half received a placebo plaster.
At the beginning of the trial, the participants underwent an MRI scan to record the scarring or lesions on the brain which are present in MS patients. Over the course of nine months, all the patients were scanned on a regular basis for new or worsening lesions which can be a tell-tale sign of relapse.
The results at the end of the trial showed that the total number of new MRI lesions did not differ significantly between patients receiving hookworm and those receiving placebo. However, more than half the patients on hookworm had no new lesions at all.
In addition, the scientists found an increase in the percentage of regulatory T cells found within patients who received the hookworm. These cells help to keep the immune system under control, and are deficient in MS patients. The results showed that the hookworm increases this type of cell which could be beneficial in the treatment of MS.
The findings of our study are encouraging. Whilst the results are modest in comparison to the current very potent and highly effective treatments available, some patients with milder disease or more inclined for natural treatments may consider this as an option. On the more biological level, it is worth harnessing immunoregulatory mechanisms, for example increasing regulatory T cells in MS (and possibly other autoimmune diseases). Further studies are now needed to establish whether different protocols can enhance this benefit. For instance, would a booster infection in around nine months enhance the regulatory T cells responses and enhance the clinical/radiological benefit?
Professor Pritchard is equally encouraged by the results of the trial. He said: “In essence, we were able to safely and easily deliver a living drug to humans, an organism which has long lasting modulatory effects on the immune system, given the time the adult parasite is resident in the small intestine (years). Clearly, this study has set the scene for follow up trials, where I would envisage booster infections being given to enhance the immune modulation already recorded. The dosage used in the current study (25 larvae) was the maximum permitted under regulatory guidelines, therefore boosting with this dose would be preferable to increasing the level of primary exposure.”
A full copy of the study can be found here.
More information is available from Professor Cris Constantinescu at the University of Nottingham, at firstname.lastname@example.org or Charlotte Anscombe, Media Relations Manager in the Press Office at the University of Nottingham, on +44 (0)115 74 84417, email@example.com
Notes to editors:
The University of Nottingham
Ranked 18th in the UK by the QS World University Rankings 2023, University of Nottingham is a founding member of Russell Group of research-intensive universities. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.
The University is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.The University is a major employer and industry partner - locally and globally - and our graduates are the second most targeted by the UK's top employers, according to The Graduate Market in 2022 report by High Fliers Research.
We lead the Universities for Nottingham initiative, in partnership with Nottingham Trent University, a pioneering collaboration between the city’s two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home.